Patients with Alcoholic Liver Disease Have Worse Functional Status at Time of Liver Transplant Registration and Greater Waitlist and Post-transplant Mortality Which Is Compounded by Older Age
Overview
Affiliations
Background: Worse functional status correlates with increased mortality on the liver transplant (LT) waitlist. Whether functional status affects LT outcomes equally across cirrhosis etiologies is unclear.
Aims: We evaluate the impact of functional status on waitlist and post-LT mortality stratified by etiology and age.
Methods: Functional status among US adults from 2005 to 2017 United Network for Organ Sharing LT registry data was retrospectively evaluated using Karnofsky Performance Status Score (KPS-1 = functional status 80-100%, KPS-2 = 60-70%, KPS-3 = 40-50%, KPS-4 = 10-30%). Waitlist and post-LT survival were stratified by KPS and cirrhosis etiology, including alcoholic liver disease (ALD), nonalcoholic steatohepatitis (NASH), hepatitis C (HCV), and HCV/ALD, and evaluated using Kaplan-Meier and multivariate Cox proportional hazard models.
Results: Among 94,201 waitlist registrants (69.4% men, 39.5% HCV, 26.7% ALD, 23.2% NASH), ALD patients had worse functional status compared to HCV (KPS-4: 17.2% vs. 8.3%, p < 0.001). Worse functional status at time of waitlist registration was associated with higher 90-day waitlist mortality with the greatest effect in ALD (KPS-4 vs. KPS-1: ALD HR 2.16, 95% CI 1.83-2.55; HCV HR 2.17, 95% CI 1.87-2.51). Similar trends occurred in 5-year post-LT survival with ALD patients the most harmed. Compared to patients < 50 years, patients ≥ 65 years had increased waitlist mortality at 90-days if they had HCV or HCV/ALD, and 5-year post-LT mortality regardless of cirrhosis etiology with ALD patients most severely affected.
Conclusions: In a retrospective cohort study of patients, US ALD patients had disparately worse functional status at time of LT waitlist registration. Worse functional status correlated with higher risk of waitlist and post-LT mortality, affecting ALD and HCV patients the most.
Yang Y, Li C, Hong Y, Sun J, Chen G, Ji K Heliyon. 2024; 10(18):e37821.
PMID: 39315220 PMC: 11417238. DOI: 10.1016/j.heliyon.2024.e37821.
Moosavi S, Mashhadiagha A, Taherifard E, Fallahzadeh M, Motazedian N, Sayadi M Gastroenterol Hepatol Bed Bench. 2024; 16(4):364-377.
PMID: 38313349 PMC: 10835093. DOI: 10.22037/ghfbb.v16i4.2795.
Minich A, Arisar F, Shaikh N, Herman L, Azhie A, Orchanian-Cheff A EClinicalMedicine. 2022; 50:101534.
PMID: 35812989 PMC: 9257342. DOI: 10.1016/j.eclinm.2022.101534.
Xu C, Mohamad Y, Kappus M, Boyarsky B, Ganger D, Volk M Liver Int. 2021; 41(10):2467-2473.
PMID: 34219362 PMC: 8522207. DOI: 10.1111/liv.15006.
Xu C, Yao F, Mohamad Y, Wong R, Kent D, Seetharaman S Transplant Direct. 2021; 7(2):e651.
PMID: 33437866 PMC: 7793347. DOI: 10.1097/TXD.0000000000001097.